Beta
ManageSearchChatDiscover
371109

Pharmaceutical Innovation and its Implications for Nursing, Medical Records, and Diagnostics Practice

Article

Last updated: 01 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Patient-generated health data (PGHD) refers to health-related information collected directly from patients to address health issues. In the field of cancer, PGHD is increas-ingly utilized to inform regulatory decisions and assess treat-ment quality. This data includes self-reported health and treat-ment records, patient-reported outcomes (PROs), and biometric sensor data. Advances in wireless technology, mobile devices, and the Internet of Things have facilitated the collection of PGHD both during clinical visits and in everyday life. Regula-tory and scientific entities, including the US Food and Drug Administration and the Institute of Medicine, have recognized the importance of PGHD. Aim of Work: The objective of this study is to provide a comprehensive summary of the clinical, regulatory, technical, and analytic aspects of PGHD in cancer research and health-care. The study aims to evaluate the evidence supporting the use of PGHD for monitoring symptoms, with a particular focus on patient-reported outcomes (PROs). Methods: The assessment includes a review of existing literature and frameworks surrounding PGHD. It discusses the current methods for digital phenotyping, which involves the re-al-time collection and analysis of biometric, behavioral, self-re-port, and performance data using electronic devices. Addition-ally, the study explores the analytical potential of PGHD within the context of big data and artificial intelligence in medicine. Results: The findings highlight the benefits of integrating PGHD into clinical treatment, including improved symptom monitoring and enhanced patient engagement. However, chal-lenges remain in integrating PROs and biometric data into elec-tronic medical records, analyzing complex biometric datasets, and redesigning clinical workflows. The evidence supporting the use of biometric data is currently more limited compared to that of PROs. Conclusion: Despite the existing difficulties, the potential advantages of PGHD suggest that it is likely to be increasingly incorporated into cancer research and clinical treatment. The study emphasizes the need for continued exploration of solu-tions to overcome the challenges associated with PGHD inte-gration

DOI

10.21608/mjcu.2021.371109

Keywords

Patient-Generated Health Data (PGHD), Patient- Reported Outcomes (PROs), Digital Phenotyping Cancer Research, Big Data and Artificial Intel- ligence

Authors

First Name

DOAA ALI ALYAMI, MUBARAK SAUD ALANAZI, REHAM MOHAMMAD ALSOULAIMI,NOOR FAHAD ALSHURAIM,

Last Name

NOURA ABDULLAH ALKHARJI , NORA MOHAMMED ALDOSARY , WEJDAN AMEIN ABDULLAH, JEHAN KHELAIF ALANAZI,

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Asma Saad Al-Qahtani, WAEL IBRAHIM AL GHANIM , JUMANA SAUD ALGHAMDI , MARIAM ADNAN ALKHADRAWI

Last Name

AFAF SNITAN AL- OTAIBI, NAHID AHMAD LAMFON,JEHAD HASSAN ALSHAIKH , ABDULLAH ALHUMAIDI ALHARBI

MiddleName

-

Affiliation

K

Email

-

City

-

Orcid

-

Volume

89

Article Issue

December

Related Issue

22432

Issue Date

2021-12-01

Receive Date

2024-07-31

Publish Date

2021-12-01

Page Start

3,175

Page End

3,183

Print ISSN

0045-3803

Online ISSN

2536-9806

Article File

MJCU_Volume 89_Issue December_Pages 3175-3183.pdf

PDF . 419.5kB

Link

https://mjcu.journals.ekb.eg/article_371109.html

Detail API

https://mjcu.journals.ekb.eg/service?article_code=371109

Order

371,109

Type

Original Article

Type Code

263

Publication Type

Journal

Publication Title

The Medical Journal of Cairo University

Publication Link

https://mjcu.journals.ekb.eg/

MainTitle

Pharmaceutical Innovation and its Implications for Nursing, Medical Records, and Diagnostics Practice

Details

Type

Article

Created At

30 Dec 2024